Trade-Ideas LLC identified




) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified NuVasive as such a stock due to the following factors:

  • NUVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $18.0 million.
  • NUVA has traded 114.3130000000000023874235921539366245269775390625 options contracts today.
  • NUVA is making at least a new 3-day high.
  • NUVA has a PE ratio of 45.
  • NUVA is mentioned 0.68 times per day on StockTwits.
  • NUVA has not yet been mentioned on StockTwits today.
  • NUVA is currently in the upper 20% of its 1-year range.
  • NUVA is in the upper 35% of its 20-day range.
  • NUVA is in the upper 45% of its 5-day range.
  • NUVA is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NUVA with the Ticky from Trade-Ideas. See the FREE profile for NUVA NOW at Trade-Ideas

More details on NUVA:

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. NUVA has a PE ratio of 45. Currently there are 12 analysts that rate NuVasive a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for NuVasive has been 501,700 shares per day over the past 30 days. NuVasive has a market cap of $2.7 billion and is part of the health care sector and health services industry. The stock has a beta of 0.32 and a short float of 6.5% with 8.44 days to cover. Shares are up 15.9% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates NuVasive as a


. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

Highlights from the ratings report include:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 808.2% when compared to the same quarter one year prior, rising from -$1.83 million to $12.96 million.
  • NUVA's revenue growth trails the industry average of 30.2%. Since the same quarter one year prior, revenues slightly increased by 5.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The current debt-to-equity ratio, 0.54, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 4.56, which clearly demonstrates the ability to cover short-term cash needs.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • The gross profit margin for NUVASIVE INC is currently very high, coming in at 82.12%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 6.46% trails the industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.